Best Practice & Research Clinical Haematology
Volume 19, Issue 2 , Pages 293-300 , June 2006

Myelodysplasia: When to treat and how

  • Richard A. Larson, MD (Professor of Medicine)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 773 702 6783; fax: +1 773 702 3002.

References 

  1. Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood. 2003;102:3025–3027
  2. Landi F, Onder G, Cesari M, et al. Effects of influenza vaccination on mortality among frail, community-living elderly patients: an observational study. Aging Clin Exp Res. 2003;15:254–258
  3. Venugopal P, Manson S, Preisler HD. Special clinical concerns/problems in the management of MDS and secondary acute myeloid leukemias. Cancer Treat Res. 2001;108:257–265
  4. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  5. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993;7(supplement 1):21–29
  6. Silverman LR, Holland JF, Demakos EA. Azacytidine in myelodysplastic syndromes: CALGB studies 8421 and 8921. Ann Hematol. 1994;68:A12;[abstr]
  7. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–2440
  8. Kornblith AB, Herndon JE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a cancer and leukemia group B study. J Clin Oncol. 2002;20:2441–2452
  9. Saba H, Rosenfeld C, Issa J-P, et al. First report of the phase III North American trial of decitabine in advanced myelodysplastic syndrome (MDS). Blood. 2004;104:23a;[abstr]
  10. Kantarjian HM, Ravandi F, O'Brien S, et al. Decitabine low-dose schedule (100mg/m2/course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules. Blood. 2004;104:402a;[abstr]
  11. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549–557
  12. List AF, Dewald G, Bennett J, et al. Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: results of the multicenter MDS-003 study. J Clin Oncol. 2005;23:2s;[abstr]
  13. Hugin RJ, Gill BP of Celgene Corporation. Preliminary Clinical Data presented on Revlimid (TM) in Malignant Blood Disorders, December 5, 2004, http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=650409&highlight=., http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=650409&highlight=.
  14. Deeg HJ, Shulman HM, Anderson JE, et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55–66 years of age. Blood. 2000;95:1188–1194
  15. Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood. 2002;99:1943–1951

PII: S1521-6926(05)00107-6

doi: 10.1016/j.beha.2005.11.005

Best Practice & Research Clinical Haematology
Volume 19, Issue 2 , Pages 293-300 , June 2006

Article Tools